Novo Nordisk A Slash S
Novo Nordisk A/S, headquartered in Denmark (DK), is a global leader in the pharmaceutical industry, specialising in diabetes care, obesity management, and hormone replacement therapies. Founded in 1923, the company has achieved significant milestones, including the development of innovative insulin products and GLP-1 receptor agonists that have transformed diabetes treatment. With a strong presence in Europe, North America, and Asia, Novo Nordisk is renowned for its commitment to sustainability and patient-centric solutions. Its core products, such as insulin pens and diabetes management devices, are distinguished by their advanced technology and user-friendly design. As a pioneer in diabetes care, Novo Nordisk holds a prominent market position, consistently recognised for its contributions to improving patient outcomes and advancing healthcare globally.
DitchCarbon Score
How does Novo Nordisk A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk A Slash S's score of 70 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novo Nordisk A Slash S's reported carbon emissions
In 2024, Novo Nordisk A/S reported total carbon emissions of approximately 2,261,000,000 kg CO2e. This includes 85,000,000 kg CO2e from Scope 1 emissions, 16,000,000 kg CO2e from Scope 2 (market-based), and a significant 2,160,000,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (1,215,000,000 kg CO2e) and capital goods (465,000,000 kg CO2e). The company has set ambitious climate commitments, aiming for net-zero emissions across its entire value chain by 2045. Near-term targets include a 100% reduction in absolute Scope 1 and 2 emissions by 2030, using 2024 as the base year. Additionally, Novo Nordisk aims to reduce its absolute Scope 3 emissions by 33% by 2033, also compared to the 2024 baseline. These targets align with the Science Based Targets initiative (SBTi) standards, which classify them as consistent with limiting global warming to 1.5°C. The company is committed to maintaining a minimum of 100% absolute reduction in Scope 1 and 2 emissions from 2030 through 2045, and a 90% reduction in Scope 3 emissions by 2045, both from the 2024 base year. Novo Nordisk's headquarters is located in Denmark (DK), and it operates within the pharmaceuticals, biotechnology, and life sciences sector. The company's proactive approach to sustainability reflects its commitment to addressing climate change and reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk A Slash S is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
